Nurix Therapeutics (NRIX) Liabilities and Shareholders Equity (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $535.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 9.47% year-over-year to $535.5 million; the TTM figure through May 2026 stood at $2.4 billion (changed 0.3% YoY), while the FY2025 annual figure was $688.1 million, up 2.81% from the prior year.
• Liabilities and Shareholders Equity retreated to $535.5 million in Q2 2026 per NRIX's latest filing, from $636.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $688.1 million in Q4 2025 and bottomed at $308.2 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $482.7 million across 5 years, with a median of $485.2 million in 2022.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity sank 32.9% — and 2025, when it surged 96.7%.
• Nurix Therapeutics' Liabilities and Shareholders Equity stood at $416.8 million in 2022, then slipped by 14.68% to $355.6 million in 2023, then surged by 88.23% to $669.3 million in 2024, then increased by 2.81% to $688.1 million in 2025, then fell by 22.18% to $535.5 million in 2026.
• Business Quant data shows NRIX's Liabilities and Shareholders Equity at $535.5 million in Q2 2026, $636.1 million in Q1 2026, and $688.1 million in Q4 2025.